Last updated: 29 February 2024 at 4:21pm EST

Indrani Franchini Net Worth




The estimated Net Worth of Indrani Lall Franchini is at least $3.59 Million dollars as of 27 February 2024. Ms. Franchini owns over 878 units of Alexion Pharmaceuticals stock worth over $816,903 and over the last 7 years she sold ALXN stock worth over $2,769,670. In addition, she makes $0 as Executive Vice President and Chief Compliance Officer at Alexion Pharmaceuticals.

Ms. Franchini ALXN stock SEC Form 4 insiders trading

Indrani has made over 9 trades of the Alexion Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 878 units of ALXN stock worth $160,744 on 27 February 2024.

The largest trade she's ever made was selling 6,853 units of Alexion Pharmaceuticals stock on 8 June 2020 worth over $785,971. On average, Indrani trades about 1,317 units every 92 days since 2017. As of 27 February 2024 she still owns at least 4,462 units of Alexion Pharmaceuticals stock.

You can see the complete history of Ms. Franchini stock trades at the bottom of the page.





Indrani Franchini biography

Indrani Franchini J.D. serves as Executive Vice President, Chief Compliance Officer of the Company. She is Executive Vice President, Chief Compliance Officer of Alexion. Ms. Franchini is responsible for leading Alexion’s global compliance program and co-leads the Global Corporate Compliance Committee. Ms. Franchini has extensive experience developing and building the infrastructure and company-wide standards for global compliance programs. Prior to joining Alexion in June 2017, Ms. Franchini served as Chief Compliance Officer at Hess Corporation (a leading independent energy company) from June 2012 to July 2017. She previously spent nearly ten years with Pfizer overseeing all compliance elements for the development, marketing, and promotion of its global business. Earlier in her career, Ms. Franchini served as an attorney with Milbank, Tweed, Hadley & McCloy in the firm’s New York and Tokyo offices. Ms. Franchini earned her J.D. from the University of Michigan Law School and a Bachelor of Arts from Princeton University. In addition, she spent a year as a Fulbright Fellow at the Kyushu University Graduation School in Fukuoka, Japan.



How old is Indrani Franchini?

Indrani Franchini is 48, she's been the Executive Vice President and Chief Compliance Officer of Alexion Pharmaceuticals since 2017. There are 15 older and 3 younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.

What's Indrani Franchini's mailing address?

Indrani's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.

Insiders trading at Alexion Pharmaceuticals

Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell, and Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.



What does Alexion Pharmaceuticals do?

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.



What does Alexion Pharmaceuticals's logo look like?

Alexion Pharmaceuticals Inc. logo

Complete history of Ms. Franchini stock trades at Alexion Pharmaceuticals and Alnylam Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
27 Feb 2024 Indrani Lall Franchini
EVP, CLO, and Secretary
Option 878 $159.00 $139,602
27 Feb 2024
4,462
1 Feb 2024 Indrani Lall Franchini
EVP, CLO, and Secretary
Option 5,175 $174.92 $905,211
1 Feb 2024
5,175
6 Apr 2023 Indrani Lall Franchini
EVP, CLO, and Secretary
Sale 3,500 $210.00 $735,000
6 Apr 2023
0
1 Feb 2023 Indrani Lall Franchini
EVP, CLO, and Secretary
Option 5,175 $224.91 $1,163,909
1 Feb 2023
5,175
8 Jun 2020 Indrani Lall Franchini
EVP and Chief Compliance Officer
Sale 6,853 $114.69 $785,971
8 Jun 2020
28,218
1 Jul 2019 Indrani Lall Franchini
EVP and Chief Compliance Officer
Sale 4,500 $132.78 $597,510
1 Jul 2019
29,627
28 Nov 2018 Indrani Lall Franchini
EVP and Chief Compliance Officer
Sale 2,605 $118.13 $307,729
28 Nov 2018
29,304
8 Jun 2018 Indrani Lall Franchini
EVP and Chief Compliance Officer
Sale 1,466 $118.53 $173,765
8 Jun 2018
31,909
6 Feb 2018 Indrani Lall Franchini
EVP and Chief Compliance Officer
Sale 1,459 $116.31 $169,696
6 Feb 2018
25,031


Alexion Pharmaceuticals executives and stock owners

Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: